Why BMI is only part of the picture
Regulatory indications for chronic weight-management medicines commonly use BMI thresholds alongside weight-related health conditions. CDSCO committee material has referenced BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbid condition, for particular chronic weight-management indications. The approved indication for the exact product remains the relevant reference.
What else can a doctor consider?
- Type 2 diabetes and blood-glucose treatment
- Blood pressure and cardiovascular risk
- Cholesterol and other metabolic risk factors
- Sleep apnoea and other weight-related conditions
- Gastrointestinal, gallbladder or pancreatic history
- Kidney health and hydration risks
- Current prescription and non-prescription medicines
- Pregnancy, breastfeeding or pregnancy plans
- Previous approaches to weight management
- Personal goals, expectations and ability to attend follow-up
Why Vaya does not use a pass/fail online quiz
A questionnaire can collect information, but it cannot replace a clinical assessment. Two people with the same BMI may have very different medical histories and treatment considerations. Vaya therefore uses the website to explain the process and begin contact, while the eligibility decision remains with the doctor.
What if treatment is not appropriate?
An eligibility process needs to allow for the answer to be “not appropriate” or “not appropriate right now”. A doctor may recommend a different approach, additional assessment or another healthcare pathway depending on the circumstances.
FAQs
Does submitting the Vaya form mean I am eligible?
No. It begins the process. Eligibility is determined by a doctor.
Does a high BMI automatically mean a GLP-1 is suitable?
No. BMI can be relevant, but medical history, contraindications, other medicines and the specific product indication also matter.
Can eligibility change over time?
Yes. Health status, medicines, pregnancy plans and other factors can change, which is one reason ongoing clinical review matters.